TOPLINE:

Treatment with ruxolitinib cream resulted in significant disease control over 52 weeks in a subset of children with moderate/more extensive atopic dermatitis (AD) in a randomized trial that evaluated both 0.75% and 1.5% strengths of the topical JAK inhibitor.

METHODOLOGY:

The TRuE-AD3 study evaluated long-term disease control and safety of ruxolitinib cream in children between the ages of 2 and 11 years with mild-to-moderate AD, including a subset of children with moderate and/or more extensive AD at baseline and at 52 weeks; results overall showed that disease control was maintained and well tolerated with treatment.

A total of 282 children (median age, 7 years) were randomly assigned to receive ruxolitinib cream 0.75% or 1.5%, or vehicle twice daily for 8 weeks, followed b

See Full Page